Application: dolutegravir (DTG), trade name: tivicay) was approved by the food and Drug Administration on August 12, 2013, and is a human immunodeficiency virus chemical book type 1 (HIV-1) integrase strand transfer inhibitor (insti) indicated for the treatment of HIV-1 infection in adults and children older than 12 years of age and with a body mass of at least 40 kg in combination with other antiretroviral agents.
Properties
Summary
Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just "572" the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process. On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada. On January 16, 2014, Tivicay was approved by the European Commission for use throughout the European Union.
CRO
